GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » YoY EBITDA Growth

Antengene (FRA:722) YoY EBITDA Growth : 23.81% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Antengene YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Antengene's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 23.81%.

Antengene's EBITDA per Share for the six months ended in Jun. 2024 was €-0.03.

Antengene YoY EBITDA Growth Historical Data

The historical data trend for Antengene's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene YoY EBITDA Growth Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -138.46 -2,261.29 90.23 11.89 8.73

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.17 -5.43 -40.00 24.74 23.81

Antengene YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Antengene's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.115--0.126)/ | -0.126 |
=8.73 %

Antengene's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.032--0.042)/ | -0.042 |
=23.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Antengene's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Antengene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » YoY EBITDA Growth
Comparable Companies
HKSE:03681 HKSE:02197 HKSE:02142 HKSE:09939 HKSE:02126 HKSE:02185 HKSE:01875 HKSE:06998 HKSE:01228 HKSE:06628 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
06996:Hong Kong
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Website
https://www.antengene.com
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Antengene Headlines

No Headlines